From: Extracorporeal life support as bridge to lung transplantation: a systematic review
Author, year | Patients, number | Age, years | Sex male, n (%) | Diagnosis | Ventilation strategy | Bridge time, days | Severity score pre-bridge |
---|---|---|---|---|---|---|---|
Mason, 2010 [11] | 51 | 39 ± 22 | 25 (49%) | PF 27%; COPD 19%; CF 12%; PH 9.8%; sarcoidosis 2%; other 20% | na | na | LAS 54 ± 21 |
Bermudez, 2011 [34] | 17 | 40 ± 14 | 7 (41%) | PF 35%; Re-LTx 35%; CF 23%; COPD 6% | MV | 3.2 (0 to 49) | na |
Hammainen, 2011 [38] | 16 | 41 ± 8a | 7 (58%)a | PF 37%a; PH 15%a; CF 8%a; ARDS 8%a; IP 8%a; PVOD 8%a; BOS 8%a; PGD 8%a | na | 12 (1 to 59) | na |
Shafii, 2012 [41] | 19 | 44 (23 to 60) | 10 (53%) | IP 68%; CF 16%; PH 16% | MV 13 | 6 ± 5 | LAS 87 (64 to 95) |
Nosotti, 2012 | 11 | 34 ± 13 | 5 (45%) | na | Awake 7 MV 4 | 12.1 ± 14.7 | SOFA 4.9 ± 1.4 |
Javidfar, 2012 [20] | 18 | 34 (22 to 50) | 8 (45%) | CF 44%; PF 33%; PH 11%; Other 11% | Awake 6 | 11.5 (6 to 18) | LAS 93 (90 to 94) |
George, 2012 [10] | 122 | 48 ± 16 | 74 (60%) | PF 29.5%; CF 11.5%; COPD 10.7%; PH 2.5%; other 45,8% | na | na | LAS 73.9 ± 21.4 |
Fuehner, 2012 [26] | 26 | 44 (23 to 62) | 21 (81%) | PF 35%; PH 27%; CF 19%; BOS 12%; sarcoidosis 4% | Awake 19 MV 7 | 9 (1 to 45) | SOFA 7 (6 to 12) |
Hoopes, 2013 [32] | 31 | 45 ± 15 | 21 (67%) | PF 29%; CF 23%; ILD 13%; ARDS 10%; PVOD 10%; PH 6%; BOS 3%; IP 3%; CWP 3% | Ambulatory 18 13 VM | 11 (2 to 53) | LAS >50 |
Anile, 2013 [36] | 12 | na | na | CF 92%; histiocytosis 8% | Awake 2 MV 10 | 6 ± 2.1 | na |
Toyoda, 2013 [33] | 31 | 46 ± 15a | 10 (42%)a | PF 33%a; CF 21%a; Re-LTx 13%a; scleroderma 13%a; bronchiectasis 8%a; COPD 4%a; sarcoidosis 4%a; PH 4%a | MVa | 7.1 ± 10 | LAS 87 ± 9a |
Weig, 2013 [39] | 26 | 36 (30 to 51)a | 14 (54%) | PF 62%; CF 23%; COPD 4%; Re-LTx 4%; Lung cancer 4%; sarcoidosis 4% | na | 16 (8.8 to 25)a | SOFA 9 (8.5 to 10.5)a |
Crotti, 2013 [35] | 25 | 41 ± 12 | na | PF 52%; CF 16%; PH 16%; Re-LTx 12%; ARDS 4% | Awake 10 MV 15 | 5.8 ± 4.5 versus 29.8 ± 11.5b | SOFA 5.6 ± 1.9 |
Lafarge, 2013 [40] | 36 | 31 (22 to 48) | 19 (53%) | CF 56%; PF 30%; other 14% | MV | 3.5 (2 to 7) | na |